Search results for "Allergen-specific immunotherapy"

showing 3 items of 3 documents

Evaluation of serum s-IgE/total IgE ratio in predicting clinical response to allergen-specific immunotherapy.

2009

Background: To date, no predictive tests for the clinical response to allergen-specific immunotherapy (ASI) are available. Therefore an in vivo or in vitro test would be of great value. Objective: We sought to evaluate pretreatment parameters used in diagnosing allergic rhinitis and determining serum specific IgE (s-IgE) levels, serum total IgE (t-IgE) levels, and blood eosinophil counts and to identify whether can be used to predict clinical improvement in monosensitized patients with allergic rhinitis with or without asthma treated with immunotherapy. Methods:We analyzed 279 patients who had undergone 4 years of ASI administered either by means of the subcutaneous immunotherapy (76 patien…

AdultMaleAllergySettore MED/09 - Medicina InternaRhinitis Allergic PerennialAdolescentmedicine.medical_treatmentImmunologyspecific IgEImmunoglobulin Eblood eosinophil countsYoung AdultBlood serummedicineImmunology and AllergyHumansreceiver operating characteristic curveAsthmaDesensitization (medicine)Retrospective StudiesSkin Testsserum s-IgE/total IgE ratio; allergen-specific immunotherapyHouse dust miteserum s-IgE/total IgE ratiobiologyserum-specific IgE/serum total IgE ratiobusiness.industryAllergen-specific immunotherapy; blood eosinophil counts; receiver operating characteristic curve; serum-specific IgE/serum total IgE ratio; specific IgE; total IgEArea under the curveImmunotherapyAllergensImmunoglobulin EMiddle Agedmedicine.diseasebiology.organism_classificationPrognosisAllergen-specific immunotherapyBlood Cell Counttotal IgEEosinophilsTreatment OutcomeDesensitization ImmunologicSpirometryImmunologybiology.proteinFemalebusiness
researchProduct

The future outlook on allergen immunotherapy in children: 2018 and beyond

2018

Abstract Allergen immunotherapy (AIT) is the only currently available immune-modifying and aetiological treatment for patients suffering from IgE-mediated diseases. In childhood, it represents a suitable therapeutic option to intervene during the early phases of respiratory allergic diseases such as rhino-conjunctivitis and asthma, which is when their progression may be more easily influenced. A growing body of evidence shows that oral immunotherapy represents a promising treatment option in children with persistent IgE- mediated food allergy. The efficacy of AIT is under investigation also in patients with extrinsic atopic dermatitis, currently with controversial results. Furthermore, AIT …

AllergyAllergen immunotherapymedicine.medical_specialtyAllergen-specific immunotherapy; Allergic rhinitis; Allergy; Children; Food allergy; IgE-mediated allergic diseases; Oral immunotherapy; Prevention; Sub-cutaneous immunotherapy; Sub-lingual immunotherapy; Child; Desensitization Immunologic; Food Hypersensitivity; Humans; Immunoglobulin E; Pediatrics Perinatology and Child HealthAllergySub-cutaneous immunotherapy610 Medicine & healthDiseaseReviewOral immunotherapyIgE-mediated allergic diseasesAllergic rhinitis03 medical and health sciences0302 clinical medicineQuality of life (healthcare)10183 Swiss Institute of Allergy and Asthma ResearchFood allergyFood allergyAllergic rhinitimedicineHumans2735 Pediatrics Perinatology and Child Health030212 general & internal medicineIntensive care medicineChildChildrenAsthmabusiness.industryPreventionlcsh:RJ1-570lcsh:PediatricsAtopic dermatitisImmunoglobulin Emedicine.diseaseSettore MED/38Allergen-specific immunotherapyRegimen030228 respiratory systemDesensitization ImmunologicIgE-mediated allergic diseasebusinessSub-lingual immunotherapyFood HypersensitivityItalian Journal of Pediatrics
researchProduct

Fine characterization of immunological mechanisms mediated by the major allergens of Parietaria judaica and by a hypoallergenic hybrid, rPjEDcys.

2015

Allergy is a hypersensitivity disease IgE-mediated, affecting more than 25% of the population. Actually the only curative treatment of allergies is Allergen-Specific Immunotherapy (SIT). Recombinant hypoallergenic allergen derivatives with reduced allergenic activity have been engineered to reduce side effects during SIT. Parietaria judaica (Pj) pollen contains two major allergens, Par j 1 and expressing disulphide bond variants of Par j 1 and Par j 2, was generated. The aim of this research project is to compare the immunological mechanisms activated by the major allergens of Pj and by rPjEDcys. In vitro analysis suggested that rPjEDcys has a reduced allergenity and maintains T cells react…

Parietaria judaica ; recombinant allergen ; hypoallergen ; Allergen-Specific ImmunotherapyAllergen-Specific ImmunotherapySettore BIO/11 - Biologia MolecolarehypoallergenParietaria judaicarecombinant allergen
researchProduct